Clinical observation and nursing care of interferon therapy in Respiratory Syncytial Virus (RSV) pneumonia patients
干扰素治疗呼吸道合胞病毒肺炎患儿临床观察和护理

摘要

目的 探讨雾化吸入注射用人干扰素α-1b治疗呼吸道合胞病毒（RSV）肺炎患儿的临床疗效，并总结针对性护理措施。方法 选取2024年8月至2025年9月本院收治的120例RSV肺炎患儿为研究对象，随机分为对照组（60例，常规治疗+基础护理）和观察组（60例，常规治疗+雾化干扰素α-1b+针对性护理）。比较两组临床疗效、症状缓解时间以及住院天数。结果 观察组治疗总有效率高于对照组（P<0.05）；观察组退热、咳嗽缓解、喘憋消失及肺部啰音消失时间均短于对照组，平均住院日少于对照组（P<0.05）。结论 雾化吸入注射用人干扰素α-1b联合针对性护理可有效提升RSV肺炎患儿的临床疗效，加速症状缓解，缩短住院时长，具有临床推广价值。

Abstract

Objective To evaluate the clinical efficacy of human interferon α-1b via nebulization inhalation in treating RSV pneumonia and summarize targeted nursing interventions.
Methods A total of 120 RSV pneumonia patients admitted to our hospital from August 2024 to September 2025 were enrolled. These patients were randomly divided into a control group (60 cases, conventional treatment + basic nursing) and an observation group (60 cases, conventional treatment +nebulized interferon α-1b+targeted nursing). The clinical efficacy, symptom resolution time, and hospitalization duration were compared between the two groups.
Results The observation group demonstrated significantly higher overall treatment efficacy than the control group (P<0.05). The observation group showed shorter durations for fever resolution, cough improvement, disappearance of wheezing, and resolution of lung rales, along with significantly shorter average hospital stays (P<0.05).
Conclusion   The combination of nebulized human interferon α-1b and targeted nursing effectively enhances clinical outcomes in RSV pneumonia patients, accelerates symptom resolution, and reduces hospitalization duration, demonstrating clinical applicability for widespread implementation.